Transition Therapeutics Alzheimer's Disease Drug Candidate AZD-1036
.
Alzheimer's Donation
Donate Online Now
.

Nature Medicine Publication Reports Positive Preclinical Data With Transition Therapeutics Inc. ("Transition") announced that Nature Medicine, one of the world's leading peer reviewed medical journals, has published an online version of a publication of preclinical studies with Transition's lead Alzheimer's disease drug candidate, AZD-103. The AZD-103 compound is a possible disease-modifying therapeutic drug candidate for the treatment of Alzheimer's disease. This unique class of drug candidates may provide significant advantages over the current therapies on the market. The findings in the Nature Medicine publication show that oral treatment of AZD-103 (scyllo-cyclohexanehexol) reduces accumulation of amyloid beta and amyloid beta plaques in the brain, as well as reduces or eliminates learning deficits in a transgenic mouse model of Alzheimer's disease. Transition is pursuing the clinical drug development of AZD-103 in an expedited manner and today, also announced that dosing with AZD- 103 has commenced in Phase I clinical trials.
"Publication in the prestigious journal Nature Medicine of this pioneering work from leading researchers at University of Toronto provides very strong scientific validation for the potential efficacy of AZD-103 as an Alzheimer's therapeutic. We recognize the tremendous need for effective Alzheimer's therapies and are taking all steps to accelerate the advancement of AZD-103 into Phase II clinical trials in Alzheimer's patients later this year or early 2007", said Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition.
The publication entitled "Cyclohexanehexol inhibitors of A Beta aggregation prevent and reverse Alzheimer phenotype in a mouse model," is accessible online in an electronic version at (http://www.nature.com/nm/journal/vaop/ncurrent/index.html) and will be available in a future issue of Nature Medicine (Citable publication number doi:10.1038/nm1423). The publication was authored by world-renowned Alzheimer's researchers at the University of Toronto using a widely-accepted transgenic mouse model of Alzheimer's disease.